UBS Moves Argenx to Buy, Cites Vyvgart Path to Roughly $20 Billion in Peak Sales
UBS upgraded Argenx from Neutral to Buy and raised its price target to $1,400 from $960, citing stronger-than-expected Phase 3 myositis results for Vyvgart and a pipeline that the bank views as underappreciated. The bank increased its probability-adjusted peak sales forecast for Vyvgart and highlighted potential launches beyond Vyvgart that could l…